Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.63
+0.12 (0.23%)
At close: Apr 10, 2026, 4:00 PM EDT
52.45
-0.18 (-0.34%)
Pre-market: Apr 13, 2026, 7:28 AM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 182 employees as of December 31, 2025. The number of employees increased by 90 or 97.83% compared to the previous year.
Employees
182
Change
90
Growth
97.83%
Revenue / Employee
$1,046,181
Profits / Employee
$112,500
Market Cap
2.72B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 182 | 90 | 97.83% |
| Sep 30, 2025 | 152 | 60 | 65.22% |
| Jun 30, 2025 | 133 | - | - |
| Mar 31, 2025 | 115 | 82 | 248.48% |
| Dec 31, 2024 | 92 | 59 | 178.79% |
| Dec 31, 2023 | 33 | 8 | 32.00% |
| Dec 31, 2022 | 25 | 5 | 25.00% |
| Dec 31, 2021 | 20 | 3 | 17.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Celldex Therapeutics | 198 |
| Relay Therapeutics | 192 |
| Disc Medicine | 155 |
| IDEAYA Biosciences | 145 |
| Tango Therapeutics | 137 |
SLNO News
- 4 days ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 5 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 7 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 7 days ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 7 days ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire
- 11 days ago - Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman - PRNewsWire
- 12 days ago - SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire
- 4 weeks ago - Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf - Newsfile Corp